SCHEMBL24929883

SCHEMBL24929883

CN(C)/C=N/C(=O)c1ccc(-n2nnc3cc(C(=O)N4CCC(F)(F)CC4)cnc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.48
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXRA P19793 1/20 0.35
VNN1 O95497 1/20 0.35
LRRK2 Q5S007 1/20 0.34
CCNT1 O60563 3/20 0.33
CDK9 P50750 3/20 0.33
HTR1A P08908 1/20 0.33
GABRA5 P31644 1/20 0.33
ADRA1A P35348 1/20 0.33
ADORA2A P29274 1/20 0.33
RPLP1 P05386 1/20 0.32
RPLP0 P05388 1/20 0.32
RPS17 P08708 1/20 0.32
RPSA P08865 1/20 0.32
RPS2 P15880 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30947679 1.00 HPGD (0.48) HPGDSMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL30361438 0.87 HPGD (0.46) HPGDSMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL30947687 0.87 HPGD (0.46) HPGDSMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL29259564 0.87 HPGD (0.46) HPGDSMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL29259578 0.87 HPGD (0.46) HPGDSMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL24463691 0.83 HPGD (0.53) HPGDSMN1; SMN2ALDH1A1RXRAVNN1
SCHEMBL30361471 0.82 HPGD (0.52) HPGDSMN1; SMN2MEN1KMT2ARXRA
SCHEMBL24929596 0.82 HPGD (0.57) HPGDALDH1A1RXRAVNN1LRRK2
SCHEMBL31038239 0.82 HPGD (0.49) HPGDSMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL30201327 0.82 HPGD (0.49) HPGDSMN1; SMN2MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374579-A1 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING EPIRIUM BIO INC. 2024-11-14 US disclosed
CN-118201926-A Bicyclic PGDH inhibitors and methods of making and using the same 埃皮里姆生物股份有限公司 2024-06-14 CN disclosed
EP-4377314-A1 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING Epirium Bio Inc. (US) 2024-06-05 EP disclosed
WO-2023009618-A1 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING EPIRIUM BIO, INC. (US) 2023-02-02 WO disclosed
WO-2023009618-A1 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING EPIRIUM BIO, INC. (US) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374579-A1 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING HPGD, HPGDS, GCDH HPGD 1/4885SMN1; SMN2 4523/4885MEN1 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.